Switching antiretroviral regimes for the treatment of HIV: safety implications.
作者： Laia Utrillo , Francesc Vidal , Teresa Puig , Pere Domingo
DOI: 10.1080/14740338.2016.1206076
关键词:
摘要: ABSTRACTIntroduction: There are multiple reasons to switch from a virologically successful antiretroviral regimen. Some of them related toxicity. Lately, combination treatment (cART) switches have often been drug-drug interactions which may also eventually entail safety issues as well.Areas covered: The purpose this review is analyze causes switching between cART regimes issues. most relevant papers were selected and summarized.Expert opinion: Switching has popular strategy address throughout the era. myriad studies paralleled study release into clinical practice new drugs with different improved profiles. Most in improving toxicity while keeping HIV replication under control. However, it should be taken account that, whenever drug given, there poss...
core.ac.uk 
sci-hub.se 参考文章(88)
Juan Pasquau, Elisabeth Deig, Enric Pedrol, Pompeyo Viciana, Mariona Tasias, Alberto Arranz, Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT Revista Espanola De Quimioterapia. ,vol. 27, pp. 93- 97 ,(2014)
Félix Gutiérrez, Mar Masiá, The role of HIV and antiretroviral therapy in bone disease. Aids Reviews. ,vol. 13, pp. 109- 118 ,(2011)
R Rubio, O Serrano, J Carmena, V Asensi, S Echevarría, J Flores, E Ribera, M Zarraga, A Ocampo, B De La Fuente, MA Sepúlveda, AI Mariño, C Minguez, R Vicent, JA Cartón, B Moyano, H Esteban, B Mahillo, L Serrano, J González-García, , Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. Hiv Medicine. ,vol. 11, pp. 545- 553 ,(2010) , 10.1111/J.1468-1293.2010.00827.X
AB Hansen, N Obel, H Nielsen, C Pedersen, J Gerstoft, Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. Hiv Medicine. ,vol. 12, pp. 157- 165 ,(2011) , 10.1111/J.1468-1293.2010.00864.X
Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine. ,vol. 356, pp. 1723- 1735 ,(2007) , 10.1056/NEJMOA062744
Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, Martin Fisher, Ian Williams, Margaret Johnson, Chloe Orkin, Fabian Chen, Vincent Lee, Alan Winston, Mark Gompels, Julie Fox, Karen Scott, David T Dunn, None, Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial The Lancet HIV. ,vol. 2, pp. e417- e426 ,(2015) , 10.1016/S2352-3018(15)00176-9
M Bloch, WWY Tong, J Hoy, D Baker, FJ Lee, R Richardson, A Carr, , Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks Hiv Medicine. ,vol. 15, pp. 373- 380 ,(2014) , 10.1111/HIV.12123
Colette Smith, Lene Ryom, Antonella d'Arminio Monforte, Peter Reiss, Amanda Mocroft, Wafaa El‐Sadr, Rainer Weber, Matthew Law, Caroline Sabin, Jens Lundgren, None, Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study Journal of the International AIDS Society. ,vol. 17, pp. 19512- 19512 ,(2014) , 10.7448/IAS.17.4.19512
Eugènia Negredo, Pere Domingo, Núria Pérez-Álvarez, Mar Gutiérrez, Gracia Mateo, Jordi Puig, Roser Escrig, Patricia Echeverría, Anna Bonjoch, Bonaventura Clotet, Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study) Journal of Antimicrobial Chemotherapy. ,vol. 69, pp. 3368- 3371 ,(2014) , 10.1093/JAC/DKU300
Sharon Walmsley, Janet Raboud, Jonathan Angel, Tony Mazzulli, Sandy Shen, Lidia Casciaro, Charlene Young, George Moussa, Kevin Gough, Anita Rachlis, Jill Hopkins, Long-Term Follow-up of a Cohort of HIV-Infected Patients Who Discontinued Maintenance Therapy for Cytomegalovirus Retinitis Hiv Clinical Trials. ,vol. 7, pp. 1- 9 ,(2006) , 10.1310/9M23-QN0X-W6N8-80JD